Sloan-Kettering Institute for Cancer Research

Memorial Sloan Kettering Cancer Center

Ludwig Institute for Cancer Research Limited

Sloan-Kettering Institute

Institute of Molecular Biology and Genetics National Academy of Science of Ukraine

Other

Institute for Molecular Biology and Genetics National Academy of Science of Ukraine

Institute of Molecular Biology and Genetics National Academy of Sciences of Ukraine

Kenneth O Lloyd

Lloyd J Old

Herbert F Oettgen

M Jules Mattes

Carlos Cordon-Cardo

Gerd J Ritter

Ivan Tarasovich Gout

Anne Murray

George Mark

Beatrice Yin

Ramziya Kiyamova

Valeriy Filonenko

Serhiy Souchelnytskiy

Samuel J Danishefsky

Philip O Livingston

Myron R Melamed

Connie L Finstad

Shun-ichiro Ogata

Alan N Houghton

Wolfgang J Rettig

Lloyd Old

Anthony P Albino

Hiroshi Yamaguchi

Bo Dupont

Yasuo Morishima

Timothy M Thomson

Nancy Collins

Koichi Furukawa

Wolfgang G Dippold

Bernd R Anger

Victor Behar

Hisami Ikeda

Peter W Glunz

Govindaswami Ragupathi

Dalibor Sames

Samuel Hintermann

Junichi Sakamoto

Francisco X Real

Karl-Anders Karlsson

John L Lewis, Jr

Willet F Whitmore

Ryuzo Ueda

J Gregory Cairncross

H Richard Beresford

Donna M Morrissey

Eileen A Friedman

Jennifer Ng

Carolos Cordon-Cardo

Valery Kudryashov

Hans-Joachim Feickert

Karen Chorney

Yves Fradet

Willet F Whitemore, Jr

Lucy T Li

Linda Roux

Jerzy Szkudlarek

Goran Larson

Nicklas Stromberg

Jan Thurin

Warren E Enker

Luiz R Travassos

Clifford S Pukel

Beatrice W T Yin

Joel Sheinfeld

Mryon R Melamed

David S Schrump

Sheila R Fortunato

Ivan Gout

Viktorovich Filonenko

The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Antibodies directed to membrane transporter NaP12b (SLC34A2) and uses thereof in cancer therapy

Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Membrane transporter NaPi2b (SCL34A2) epitope antibodies

Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

The present invention provides novel glycoconjugates such as glycopeptides, as well as convergent methods for the synthesis thereof. An exemplary preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the glycoconjugates of the invention.

Glycopeptide conjugates and uses thereof

The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the diagnosis of a cancer which expresses CA125 by detecting CA125-expressing cells in the blood or other fluids of patients. This invention also provides a method of producing CA125 protein. This invention also provides a method of silencing CA125 protein production. Finally, this invention provides a method to treat or prevent cancer using a vaccine comprising CA125 nucleic acid or protein.

Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof

Synthesis of glycoconjugates of the lewis Y epitope and uses thereof

The present invention provides a method of synthesizing an allyl pentasaccharide having the structure:

Synthesis of glycoconjugates of the lewis y epitope and uses thereof

This invention provides a composition useful for diagnosing cancer which specifically recognizes a galactosyl-globoside. Preferably, the composition is a monoclonal antibody which specifically recognize the galactosyl-globoside antigen, gal-Gb4. Additionally, the present invention provides two hybridoma cell lines, designated J309 and D579, which produce monoclonal antibodies that specifically recognize gal-Gb4. The invention also provides a method of diagnosing a carcinoma which comprises contacting a sample from a human subject with a composition which specifically recognizes a galactosyl-globoside antigen and is labeled with a detectable moiety, under suitable conditions so as to form a detectable complex. The amount of formed complex is then quantified and correlated with values obtained from subjects devoid of carcinomas. Another aspect of the invention provides a method of treating carcinoma which comprises administering an effective amount of galactosyl-globoside or an analog thereof and a pharmaceutically carrier to stimulate the body production of antibodies.

Monoclonal antibodies which specifically recognize galactosyl-globoside,

The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewis.sup.a or Lewis.sup.b antigens, the presence of the Lewis.sup.a antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewis.sup.b antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor. The invention provides a method of determining whether a human female subject is susceptible to urogenital infection which comprises determining whether the subject is a secretor according to the hereinabove-described methods, a secretor being susceptible to such an infection. The present application also provides a method of disstinguishing urothelial carcinoma from normal tissue, and identifying human germ cell tumor as seminoma or nonseminoma. Finally, the invention provides a panel comprising some or all of the monoclonal antibodies H 29-36 (ATCC No. HB 8248), S8 (ATCC No. HB 9036), T 174 (ATCC No. HB 8242), T 218 (ATCC No. HB 8249), P 12 (ATCC No. HB 8551), F 3 (ATCC No. HB 8217), and K 21 (ATCC No. HB 8549).

Blood group antigen panel

Monoclonal antibodies to human antigens present on a majority of human cells are described. These mAbs have use in a method for isolating mAb for less expressive antigens, such as cancer antigens, or other antigens associated with particular abnormalities, disorders or disease state. The latter mAbs may be weaker than or not present to such an extent as the first mentioned mAbs. For example, these less expressive mAbs would be useful for cancer diagnosis, especially in the early stages, and for cancer treatment as well where the cancer cell is the target cell for the mAb. The mAb can be tagged with a tissue destructive agent such as a radio-label, a toxin, a chemical poisen, and the like. Some of the mAbs described, subset tumors of particular types and so are useful for tumor subclassification. The mAbs described are also useful in analyzing the properties and functions of their respective antigens in human cells.

Method for production of monoclonal antibodies for cancer diagnosis and

This invention relates to monoclonal antibodies recognizing the gp130 antigen of human cells. Monoclonal antibodies which recognize distinct determinants on this antigen and methods of detecting the determinants by immunoassay with the monoclonal antibodies which recognize them are disclosed. The monoclonal antibodies are useful in the detection of the gp130 antigen and human cells including melanoma which contain this antigen.

Monoclonal antibodies to melanoma cells

This invention provides a monoclonal antibody, produced by the hybridoma cell line designated GXM1, which specifically binds to a human class 1tumor antigen. This invention also provides a human monoclonal antibody, produced by a hybridoma cell line designated HJM1, which specifically binds to each of the ganglioside antigens GD2, GD3, GM3 and GD1b. This invention further provides a human monoclonal antibody, produced by a hybridoma cell line designated FCM1, which specifically binds to the ganglioside antigens GM3 and GD1a. Finally, this invention provides a human monoclonal antibody, produced by a hybridoma cell line designated DSM1, which specifically binds to a human class 2 tumor protein antigen.

Human monoclonal antibodies to cell surface antigens of melanoma

This invention concerns a new monoclonal antibody (mAb) 4C, recognizing a specific antigen, Leu 200, found in human hematopoietic tissues. The monoclonal antibody precipitates a series of glycoproteins (Leu 200) with a molecular weight range of about 190,000 to 230,000 from both T- and B-cell lines. The series of glycoproteins resolves into four discrete glycoprotein bands, the distribution of which varies according to the cell lines. Bands 3 and 4 predominate in a majority of T-cells whereas band 2 predominates in B cells. Thus, a Leu 200 antigen subset distribution is possible with mAb 4C. Bands 1, 2, 3, 4 have apparent molecular weights of 230K, 215K, 205K, and 190K respectively, with differences in their carbohydrate moieties. nAb 4C is a IgG sub two a,kappa immunoglobulin. 4C has potential use in leukemia, hematopoietic cell differentiation and transplantation diagnoses and therapy.

Monoclonal antibody for human hematopoietic glycoproteins and method

A panel of monoclonal antibodies produced from normal human lung fibroblasts and human lung tumors as immunogen is used to diagnose the presence of lung tumors and differentiate between those which are benign and those which are cancerous.

Monoclonal antibodies to human lung cancers and method

Growing community of inventors

Bronx, NY, United States of America

Kenneth O Lloyd